• Attendance/ Introductions

    • Najib Rehman (??)
      • working with a data integrator to support swiss pharma clients on CTs; DLT to speed things up a bit
    • Willy (??)
    • Leah Houston
    • Bernard
    • Catherine

    • Robert's presentation
      • scale: billions of transactions in a 3-hour overnight crunch period
      • trial generating valuable material and guidance for industry governance processes
      • interaction of technical, operations, and compliance/governance groups
      • API and Schemata —> starting point for standardization
    • "This is an industry that runs on standards"

      • GS1 for txn info and ids,

      • Everyone obvi wants to look with the W3C standards

        • all the examples in the spec are very consumer-based; bias and mental model

      • "Challenges"

        • Challenge #1: Scale
        • Standards and misfit b/w W3C as-is today and these use-cases
        • Challenge #2: Retention req (6 year record-keeping obligation) —> binding VCs and VPs need to be archival/auditable for 6 years!
          • VP ephemerality (in VC spec)
          • Lesson#1 Identifier ←→ Company name binding needs to be durable/archival
        • Challenge #3: How does Company B know that A was handling credentials properly and according to industry and/or regulatory rules, if they just get a log or a recipt?
          • Logging of credential exchanges? reusing credentials falsely, replay attacks, etc?
          • Out of scope for now, but we're starting to look at the possibility of a third-party compliance auditor or guarantor? Do they attach additional VCs?

      • security risks

        • drug cartel made 25 shell corps to hide infiltration in a drug supply chain
          • mitigations of legal identity issues
          • drug cartels have a big R&D budgets for impersonation, counterfeiting, etc— way more tech savvy than many supply chain actors such as smalltown pharmacies!

  • Q&A

    • Najid: FMD (I used to work for Pfizer so I know the DCSCA and serialization!); what are your thoughts on B2B2P and P identity?
      • Orphan disease area? Teaching hospital ... Therapies and vectors?
      • Volume and complex stakeholders...
      • Standards around labeling (tagging blood in loop); 200K-1.3m$ therapies! the liabilities (and stakes) are massive there
      • How do we get everybody on board? Some people are incentivized for intransparency
    • Bob: One of the pilots in the FDA program was a very expensive personalized drug: the roundtrip; temp control in transit; temperature indicator behind a bar code, so that bar code changed
    • Georg: Novartis is looking into this for Kamriah; validated (manual) process for now